Neuphoria Therapeutics Inc (NEUP) Stock Forecast
NEUP analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $7.00 average of analyst targets
- Upside to target
- +112.1% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.56
- 52-week range
- $3.24 – $15.40
NEUP analyst ratings
1 analystsNumber of analysts at each rating.
NEUP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NEUP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | −$2.43 | −$2.43 | −$2.43 | −$1.85 | −31.1% | 1 |
| Next fiscal year (FY2028) | −$2.46 | −$2.46 | −$2.46 | −$2.43 | −1.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NEUP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Next quarter (Dec '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (FY2027) | $0 | $0 | $0 | −100.0% | 1 |
| Next fiscal year (FY2028) | $0 | $0 | $0 | 0.0% | 1 |
NEUP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NEUP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | −$2.43 | −$2.43 | −$2.43 | −$2.43 | −$2.43 | 0.0% | 0 up · 1 down |
| Next fiscal year (FY2028) | −$2.46 | −$2.46 | −$2.46 | −$2.46 | −$2.46 | 0.0% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NEUP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NEUP beat in 6 of 10.
What analysts expect from NEUP
1 analysts cover Neuphoria Therapeutics; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.00, 112.1% above the latest close of $3.30. Analysts expect earnings of −$2.43 per share for FY2027, −31.1% from a year earlier. For FY2028 the average estimate is −$2.46 per share. Neuphoria Therapeutics beat the EPS estimate in 6 of the last 10 quarters.
Related: NEUP income statement, NEUP key metrics, NEUP chart. See the NEUP stock overview for the latest quote and news.
NEUP forecast FAQ
What is Neuphoria Therapeutics's price target?
The average analyst price target for Neuphoria Therapeutics is $7.00, 112.1% above the latest close of $3.30.
Is Neuphoria Therapeutics a buy, hold or sell?
Of 1 analysts covering Neuphoria Therapeutics, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Neuphoria Therapeutics's EPS forecast?
Analysts forecast −$2.43 per share for FY2027 (range −$2.43 to −$2.43); for FY2028 the estimate is −$2.46.
When does Neuphoria Therapeutics report earnings?
Neuphoria Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.56.
Does Neuphoria Therapeutics usually beat earnings estimates?
Neuphoria Therapeutics reported EPS at or above the analyst estimate in 6 of the last 10 quarters.